SOURCE: Nuvilex, Inc.

Nuvilex, Inc.

June 26, 2013 08:30 ET

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare's Hard Targets

NEW YORK, NY--(Marketwired - Jun 26, 2013) - Nuvilex, Inc. (OTCQB: NVLX) executives aren't daunted by the statistics. As a matter of fact, they're aware the research they do is directed towards attacking what the company's Chief Operations Officer, Dr. Gerald Crabtree, calls two of cancer's "hard targets." "Pancreatic cancer and brain cancers represent two such targets. Pancreatic cancer because it doesn't present overt symptoms until the cancer is at an advanced stage; therefore, it is more difficult to treat effectively, and the result is that the survival of patients with advanced pancreatic cancer is usually only several weeks to a few months. Brain cancers are another hard target because many of our most effective cancer drugs cannot cross the 'blood-brain' barrier to attack the tumor."

Make no mistake about it: the statistics aren't pretty. The American Cancer Society estimates that, in 2013, more than 45,000 people will be diagnosed with pancreatic cancer and over 38,000 will die from the disease in the US alone. It is the fourth most deadly form of cancer in the world and a disease where no amount of money or fame will help change those statistics. Recently it has claimed the lives of well known names like Apple's Steve Jobs, actor Patrick Swayze and Nobel Prize recipient Dr. Ralph Steinman. 

Both pancreatic cancer and cancers of the brain are the hard targets that Nuvilex has invested its research into in order to develop treatments with its cell encapsulation technology and future medical marijuana studies. The company has close to $30 million invested in its unique live-cell encapsulation technology, and it's using that technology, combined with the cancer killing drug ifosfamide, in clinical trials for the treatment of advanced, inoperable pancreatic cancer.

Eli Lilly's Gemzar is the only drug approved by the FDA as a single agent for the treatment of advanced pancreatic cancer, and is the current "gold standard" for the disease. Eli Lilly has enjoyed sales of over $10 billion for the drug for all indications, but Gemzar accounts for the majority of the sales of all drugs for advanced pancreatic cancer.

It is Nuvilex's goal to make an impact on that market with its treatment. Over the years, several drugs have been combined with Gemzar in an effort to improve survival, but these efforts have only been marginally successful. In fact, since 1990, 33 pivotal (for marketing approval) Phase III clinical trials have been conducted -- only 3 were successful.

Continue reading this article at

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors to become better informed on small cap companies. For more information:

Contact Information